Rheumatoid arthritis and metabolic disorders
Authors:
Stela Kašperová 1; Lenka Tarabčáková 2; Barbora Kašperová 3; Em Ke Šteňová 1
Authors place of work:
I. interná klinika Lekárskej fakulty Univerzity Komenského v Bratislave a Univerzitnej nemocnice v Bratislave
1; Reumatologická ambulancia, Nemocnica Sv. Michala, Bratislava
2; Klinika onkohematológie LF UK a NOÚ, Bratislava
3
Published in the journal:
Vnitř Lék 2021; 67(E-2): 18-24
Category:
Summary
Rheumatoid arthritis is a chronic autoimmune inflammatory disease associated with multiple metabolic alterations and increased cardiovascular risk. It is supposed that visceral obesity seems to be a connection between rheumatoid arthritis and cardiovascular diseases. Obesity is not only associated with increased disease activity and worsened quality of life in this group of patients, but also determines the effectiveness of treatment. Biological therapy interferes with metabolic changes, too. Therefore, there is a tendency to select the right anticytokine preparation in the first line of treatment to reduce not only disease activity but also affect aspects of metabolic syndrome and comorbidites, thereby reducing cardiovascular risk and patient’s mortality. This work offers a basic overview of the associations between rheumatoid arthritis and metabolic disorders, describes the impact of biological therapy on individual components of the metabolic syndrome.
Keywords:
anticytokine treatment – cardiovascular risk – metabolic syndrome – rheumatoid arthritis
Zdroje
1. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Annals of the Rheumatic Diseases 2017; 76(1): 17–28. Dostupné z DOI: http://dx.doi.org/10.1136/annrheumdis-2016-209775.
2. Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Annals of the Rheumatic Diseases 2014;73(1): 62-68. Dostupné z DOI: https:// 10.1136/annrheumdis-2013-204223.
3. Houge, Ingrid Sæther, et al. Mortality is increased in patients with rheumatoid arthritis or diabetes compared to the general population–the Nord-Trøndelag Health Study. Scientific reports, 2020; 10(1): 1–10. Dostupné z DOI: https://doi.org/10.1038/s41598- 020-60621-2.
4. Kerekes, György, et al. Rheumatoid arthritis and metabolic syndrome. Nature Reviews Rheumatology, 2014; 10(11): 691. Dostupné z DOI: https://doi:10.1038/nrrheum. 2014.121.
5. Van Der Helm-Van Mil, A H M, et al. A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Annals of the rheumatic diseases, 2008; 67(6): 769–774. Dostupné z DOI: https://doi:10.1136/ard.2007.078832.
6. MacDonald, Iona J, et al. Associations between adipokines in arthritic disease and implications for obesity. International journal of molecular sciences, 2019; 20(6): 1505. Dostupné z DOI: https://doi:10.3390/ijms20061505.
7. Dessein, Patrick H, et al. Rheumatoid arthritis impacts on the independent relationships between circulating adiponectin concentrations and cardiovascular metabolic risk. Mediators of inflammation, 2013, 2013. Dostupné z DOI: https://doi:10.1155/2013/461849.
8. Lago, Francisca, et al. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine & growth factor reviews, 2007; 18(3–4): 313–325. Dostupné z DOI: https://doi:10.1016/j.cytogfr.2007.04.007.
9. Francisco Vera, et al. Adipokines: Linking metabolic syndrome, the immune system, and arthritic diseases. Biochemical pharmacology, 2019. Dostupné z DOI: https://doi.org/ 10.1016/j.bcp.2019.03.030.
10. Olama, Shereen M; Senna, Mohammed K; Elarman Mohammed. Synovial/serum leptin ratio in rheumatoid arthritis: the association with activity and erosion. Rheumatology International, 2012; 32(3): 683–690. Dostupné z DOI: https://doi.org/10.1007/s00296-010-1698-5.
11. Tanti, Jean-François, et al. Implication of inflammatory signaling pathways in obesity- -induced insulin resistance. Frontiers in endocrinology, 2013; 3: 181. Dostupné z DOI: https:// doi.org/10.3389/fendo.2012.00181.
12. Oravec S. Hyperlipoproteinémie, úvod do problematiky porúch metabolizmu lipoproteínov. Univerzita Komenského v Bratislave: 2012: 47–50. ISBN 978-80-223-3290-3.
13. Charles-Schoeman, Christina, et al. Abnormal function of high – density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 2009; 60(10): 2870–2879. Dostupné z DOI: https://doi.org/10.1002/art.24802.
14. Ruscitti, Piero, et al. Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. PLoS medicine, 2019, 16(9). Dostupné z DOI: https://doi:10.1371/journal.pmed.1002901.
15. Everett, Brendan M, et al. Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. Journal of the American College of Cardiology, 2018; 71(21): 2392–2401. CANTOS. Dostupné z DOI: https://doi:10.1016/j.jacc.2018.03.002.
16. Genovese, Mark C, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis & Rheumatology, 2015; 67(6): 1424–1437. Dostupné z DOI: https://doi.org/10.1002/ art.39093.
17. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Annals of the rheumatic diseases, 2009; 68(4): 460–469. Dostupné z DOI: http:// dx.doi.org/10.1136/ard.2008.101964.
18. Daïen, Claire Immediato, et al. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Annals of the rheumatic diseases, 2012; 71(6): 862–868. Dostupné z DOI: http://dx.doi.org/10.1136/annrheumdis- 2011-201148.
19. Schultz O, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PloS one, 2010; 5(12). Dostupné z DOI: https://doi:10.1371/journal.pone.0014328.
20. Szekanecz Z, et al. Autoimmune atherosclerosis in 3D: how it develops, how to diagnose and what to do. Autoimmunity reviews, 2016; 15(7): 756–769. Dostupné z DOI: https:// doi.org/10.1016/j.autrev.2016.03.014.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
2021 Číslo E-2
Najčítanejšie v tomto čísle
- Non-pharmacological treatment of gout
- Serum butyrylcholinesterase/HDL-cholesterol ratio and atherogenic index of plasma in patients with fatty liver disease
- Rheumatoid arthritis and metabolic disorders
- Application of surgical mask with high-flow nasal cannula (HFNC) leads to improved oxygenation in patients with COVID-19: a set of case reports